Condition

Acute Lymphoblastic Leukemia, in Relapse clinical trials and research

• 16Clinical trials
• 18Countries

Newest Acute Lymphoblastic Leukemia, in Relapse clinical trials

All recruiting trials (16)

• Nanobody CD5 CAR‑T for relapsed or refractory CD5‑positive T‑cell cancers

  This will test a CD5-targeted CAR‑T cell treatment using patients' own or donor-derived cells to try to help people with relapsed or refractory CD5+ T‑cell leukemias and lymphomas.

  Recruiting at 3 sites Phase 1/2 Beijing GoBroad Hospital · Beijing, Beijing Municipality and 3 other locations · NCT07070323

• CAR-T cell therapy for adults with relapsed or refractory leukemia and lymphoma

  This study is testing a new CAR-T cell therapy to see if it can help adults with tough-to-treat leukemia or lymphoma feel better and fight their cancer.

  Recruiting at 2 sites Phase 1 Fudan University · Nanchang, Jiangxi and 1 other locations · NCT06445803

• CIK cell therapy for relapsed or refractory B‑cell acute lymphoblastic leukemia with early CAR‑T dysfunction

  We are testing whether giving regular or mRNA‑modified CIK cells helps children and young adults with relapsed or refractory B‑cell ALL who show early CAR‑T cell exhaustion stay free of relapse or disease progression longer.

  Recruiting Beijing GoBroad Hospital · Beijing, Beijing Municipality · NCT06389305

• Comparing CD19 and CD22 CAR T-cell therapies for treating relapsed B-ALL

  This study is testing whether giving patients with relapsed B-cell Acute Lymphoblastic Leukemia two different types of CAR T-cell therapies one after the other works better than just one type followed by a stem cell transplant.

  Recruiting Beijing GoBroad Hospital · Beijing, Beijing Municipality · NCT06343090

• Donor-derived CD19 CAR T cells with allo‑HSCT followed by donor-derived CD22 CAR T cells for relapsed/refractory B‑ALL

  This study tests donor-derived CD19 CAR T cells followed by an allogeneic stem‑cell transplant and sequential donor-derived CD22 CAR T cells in children and adolescents (1–18 years) with relapsed or refractory CD19+/CD22+ B‑ALL who cannot provide their own cells.

  Recruiting Phase 1 Beijing GoBroad Hospital · Beijing, Beijing Municipality · NCT06326008

• CD5 CAR T-cell therapy for relapsed or refractory T-cell malignancies

  This study is testing a new CAR T-cell therapy for people with hard-to-treat T-cell cancers to see if it is safe and how well it works.

  Recruiting at 3 sites Phase 1/2 Beijing GoBroad Hospital · Beijing, Beijing Municipality and 3 other locations · NCT06316856

• CD7 CAR-T therapy for patients with relapsed or refractory T-cell malignancies

  This study is testing a new type of CAR-T therapy for people with T-cell leukemia that hasn't responded to other treatments to see if it can help them feel better.

  Recruiting at 3 sites Phase 1/2 Beijing GoBroad Hospital · Beijing, Beijing Municipality and 3 other locations · NCT06316427

• CAR T Cell Therapy for Resistant B-cell Cancers

  This study is testing a new CAR T cell therapy to see if it can safely help people with tough-to-treat B-cell cancers like leukemia and lymphoma.

  Recruiting Phase 1/2 Essen Biotech · Beijing, Beijing Municipality · NCT06213636

• Bortezomib treatment for relapsed or refractory acute lymphoblastic leukemia

  This study is testing if a new treatment using bortezomib can help adults with hard-to-treat acute lymphoblastic leukemia feel better and prepare for a stem cell transplant.

  Recruiting Phase 2 Instituto do Cancer do Estado de São Paulo · São Paulo, São Paulo · NCT06034561

• Understanding why CAR T cells don't last in leukemia treatment

  This study looks at kids and young adults with leukemia to see why CAR T cells don't stick around long enough after treatment and what might help them last longer.

  Recruiting at 3 sites University College, London · London and 2 other locations · NCT05809284

• Ruxolitinib and venetoclax added to chemotherapy for children and young adults with relapsed or refractory ALL/LBL

  This trial tests whether adding ruxolitinib and venetoclax to dexamethasone, cyclophosphamide and cytarabine helps children and young adults with relapsed or refractory acute lymphoblastic leukemia or lymphoblastic lymphoma who have IL7R/JAK-STAT pathway changes.

  Recruiting at 3 sites Phase 1/2 Princess Maxima Center for Pediatric Oncology · Vienna and 32 other locations · NCT05745714

• CD19-targeted CAR‑T cell treatment for relapsed or refractory B‑cell leukemias and lymphomas

  This study will try an experimental CD19-targeted CAR‑T cell therapy in children and adults whose CD19+ B‑cell leukemias or lymphomas have relapsed or not responded to at least two prior treatments.

  Recruiting Phase 1 Hospital Israelita Albert Einstein · São Paulo, São Paulo · NCT05705570

• Combination treatment for children with relapsed or refractory blood cancers

  This study is testing a new combination of medications to see if it can help children and young adults with tough-to-treat blood cancers feel better and improve their chances of recovery.

  Recruiting at 5 sites Phase 1/2 Princess Maxima Center for Pediatric Oncology · Vienna and 35 other locations · NCT05658640

• Combining an anti-PD1 antibody with CAR T-cell therapy for young patients with relapsed leukemia

  This study is testing if adding a new drug to CAR T-cell therapy can help young patients with relapsed leukemia get better results from their treatment.

  Recruiting at 13 sites Phase 1/2 Assistance Publique - Hôpitaux de Paris · Bordeaux and 12 other locations · NCT05310591

• Venetoclax treatment for high-risk blood cancers in young patients

  This study is testing a new combination of a drug called venetoclax with chemotherapy to see if it helps young patients with high-risk blood cancers feel better while keeping side effects low.

  Recruiting at 5 sites Phase 1 Dana-Farber Cancer Institute · San Francisco, California and 4 other locations · NCT05292664

• Treatment for relapsed or refractory CD19-positive leukemia using allogeneic memory T-cells

  This study is testing a new CAR T-cell therapy using special immune cells to see if it can help young people with tough-to-treat leukemia feel better.

  Recruiting Phase 1 St. Jude Children's Research Hospital · Memphis, Tennessee · NCT04881240

Related topics

Quick answers

How many Acute Lymphoblastic Leukemia, in Relapse clinical trials are recruiting right now?

16, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 18 countries. The most sites are in China (8 trials), France (3 trials), United Kingdom (3 trials), United States (2 trials), Austria (2 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 1/2: 7, Phase 1: 5, Phase 2: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →